JPH10504561A - 治療に有用なスピロ−アザ二環式化合物 - Google Patents
治療に有用なスピロ−アザ二環式化合物Info
- Publication number
- JPH10504561A JPH10504561A JP8507995A JP50799596A JPH10504561A JP H10504561 A JPH10504561 A JP H10504561A JP 8507995 A JP8507995 A JP 8507995A JP 50799596 A JP50799596 A JP 50799596A JP H10504561 A JPH10504561 A JP H10504561A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- enantiomer
- formula
- pharmaceutically acceptable
- acid addition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式I (式中、Rは水素またはメチルであり、そしてnは1または2である)の化合 物またはその薬学的に許容しうる酸付加塩もしくはエナンチオマー。 2.Rが水素である請求項1記載の化合物またはその薬学的に許容しうる酸付加 塩もしくはエナンチオマー。 3.スピロ〔1−アザビシクロ〔2.2.2〕オクタン−3,5′−オキサゾリジン〕− 2′−オンまたはその薬学的に許容しうる酸付加塩もしくはエナンチオマー。 4.(+)−スピロ〔1−アザビシクロ〔2.2.2〕オクタン−3,5′−オキサゾリ ジン〕−2′−オンまたはその薬学的に許容しうる酸付加塩。 5.(−)−スピロ〔1−アザビシクロ〔2.2.2〕オクタン−3,5′−オキサゾリ ジン〕−2′−オンまたはその薬学的に許容しうる酸付加塩。 6.スピロ〔1−アザビシクロ〔2.2.1〕ヘプタン−3,5′−オキサゾリジン−2 ′−オン〕またはその薬学的に許容しうる酸付加塩もしくはエナンチオマー。 7.3′−メチルスピロ〔1−アザビシクロ〔2.2.2〕オクタン−3,5′ −オキサゾリジン−2′−オン〕またはその薬学的に許容しうる酸付加塩もしく はエナンチオマー。 8.請求項1〜7の何れかの項で定義された化合物またはその薬学的に許容し得 る酸付加塩もしくはエナンチオマーを薬学的に許容しうる希釈剤または担体と混 合して含有する医薬組成物。 9.医薬として使用される請求項1〜7の何れかの項記載の化合物またはその薬 学的に許容しうる酸付加塩もしくはエナンチオマー。 10.精神病的疾患または知的損傷疾患を治療または予防するための薬剤の製造に おける請求項1〜7の何れかの項で定義された化合物またはその薬学的に許容し うる酸付加塩もしくはエナンチオマーの使用。 11.疾患が精神分裂病、アルツハイマー病、学習障害、認識障害または注意障害 の活動亢進疾患である請求項10記載の使用。 12.不安の治療または予防のための薬剤の製造における請求項1〜7の何れかの 項で定義された化合物またはその薬学的に許容しうる酸付加塩もしくはエナンチ オマーの使用。 13.治療的に有効な量の請求項1〜7の何れかの項で定義された化合物またはそ の薬学的に許容しうる酸付加塩もしくはエナンチオマーを患者に投与することか らなる、精神病的疾患または知的損傷疾患を治療または予防する方法。 14.疾患が精神分裂病、アルツハイマー病、学習障害、認識障害または注意障害 の活動亢進疾患である請求項13記載の方法。 15.治療的に有効な量の請求項1〜7の何れかの項で定義された化合物またはそ の薬学的に許容しうる酸付加塩もしくはエナンチオ マーを患者に投与することからなる、不安を治療または予防する方法。 16.(a) 相当する式II (式中、nは請求項1で定義された通りである)の化合物を環化してRが水素 である式Iの化合物を製造する; (b) 相当する式III (式中、nおよびRは請求項1で定義された通りである)の化合物をカルボニ ル供与化合物と反応させて式Iの化合物を製造する; (c) Rが水素である相当する式Iの化合物をアルキル化してRがメチルであ る式Iの化合物を製造する;または (d) エナンチオマーの混合物から一方のエナンチオマーを分割して式Iの化 合物の一方のエナンチオマーを製造することからなり、 そして所望によりまたは必要に応じて得られた式Iの化合物またはその酸付 加塩もしくはエナンチオマーをその薬学的に許容しうる酸付加塩またはエナンチ オマーに変換する、あるいはその逆を行なう、請求項1で定義された式Iの化合 物またはその薬学的 に許容しうる酸付加塩もしくはエナンチオマーの製造法。 17.式IV (式中、nは請求項1で定義された通りである)の化合物またはその塩もしく はエナンチオマー。 18.式III (式中、nは請求項1で定義された通りであり、そしてRはメチルである)の 化合物またはその塩もしくはエナンチオマー。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9417084.2 | 1994-08-24 | ||
GB9417084A GB9417084D0 (en) | 1994-08-24 | 1994-08-24 | Compounds useful in therapy |
GB9504627.2 | 1995-03-08 | ||
GBGB9504627.2A GB9504627D0 (en) | 1995-03-08 | 1995-03-08 | Compounds for use in therapy |
PCT/SE1995/000937 WO1996006098A1 (en) | 1994-08-24 | 1995-08-22 | Spiro-azabicyclic compounds useful in therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10504561A true JPH10504561A (ja) | 1998-05-06 |
JP3708962B2 JP3708962B2 (ja) | 2005-10-19 |
Family
ID=26305509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50799596A Expired - Fee Related JP3708962B2 (ja) | 1994-08-24 | 1995-08-22 | 治療に有用なスピロ−アザ二環式化合物 |
Country Status (34)
Country | Link |
---|---|
US (2) | US5902814A (ja) |
EP (1) | EP0777671B1 (ja) |
JP (1) | JP3708962B2 (ja) |
KR (1) | KR100366331B1 (ja) |
CN (2) | CN1056846C (ja) |
AR (1) | AR031828A2 (ja) |
AT (1) | ATE192157T1 (ja) |
AU (1) | AU690735B2 (ja) |
BR (1) | BR9508751A (ja) |
CA (1) | CA2196995C (ja) |
CZ (1) | CZ289512B6 (ja) |
DE (1) | DE69516524T2 (ja) |
DK (1) | DK0777671T3 (ja) |
EE (1) | EE03399B1 (ja) |
EG (1) | EG24222A (ja) |
ES (1) | ES2145922T3 (ja) |
FI (1) | FI112868B (ja) |
GR (1) | GR3033878T3 (ja) |
HK (1) | HK1010370A1 (ja) |
HU (1) | HUT77352A (ja) |
IL (1) | IL115039A (ja) |
IS (1) | IS1852B (ja) |
MX (1) | MX9701292A (ja) |
NO (1) | NO307707B1 (ja) |
NZ (1) | NZ292289A (ja) |
PL (1) | PL183933B1 (ja) |
PT (1) | PT777671E (ja) |
RU (1) | RU2148058C1 (ja) |
SA (1) | SA95160370B1 (ja) |
SK (1) | SK282366B6 (ja) |
TR (1) | TR199501053A2 (ja) |
TW (1) | TW397837B (ja) |
UA (1) | UA54375C2 (ja) |
WO (1) | WO1996006098A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001199985A (ja) * | 1999-07-26 | 2001-07-24 | Sumika Fine Chemicals Co Ltd | 高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶 |
JP2002534525A (ja) * | 1999-01-15 | 2002-10-15 | アストラゼネカ・アクチエボラーグ | 治療において有用なスピロフロピリジンの新規なアラルキルアミン |
JP2006514946A (ja) * | 2002-12-06 | 2006-05-18 | ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート | α7受容体結合コリン作動性アゴニストを用いる炎症の阻害 |
JP2011518831A (ja) * | 2008-04-23 | 2011-06-30 | ブリストル−マイヤーズ スクイブ カンパニー | α−7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
WO2001066546A1 (fr) * | 2000-03-09 | 2001-09-13 | Mitsubishi Pharma Corporation | Composes spiro, leur procede de preparation et leur utilisation comme medicaments |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
WO2002018391A1 (en) * | 2000-08-28 | 2002-03-07 | Colorado State University Research Foundation | Compounds containing oxazolidinone moiety and uses thereof |
US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
EP1453828A2 (en) * | 2001-10-16 | 2004-09-08 | AstraZeneca AB | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
AU2003217747A1 (en) * | 2002-02-26 | 2003-09-09 | North Shore-Long Island Jewish Research Insitute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
CA2531510A1 (en) * | 2003-07-08 | 2005-01-20 | Astrazeneca Ab | Spiro '1-azabicyclo '2.2.2!octan-3,5'-oxazolidin-2'one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
EP1734941A2 (en) * | 2004-03-25 | 2006-12-27 | The Feinstein Institute for Medical Research | Neural tourniquet |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
JP2008524208A (ja) * | 2004-12-15 | 2008-07-10 | アストラゼネカ・アクチエボラーグ | ニコチン性アセチルコリン受容体リガンド |
DE602005025020D1 (de) | 2004-12-27 | 2011-01-05 | The Feinstein Inst Medical Res | Behandlung von entzündlichen erkrankungen durch el |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
CN101090895A (zh) * | 2004-12-28 | 2007-12-19 | 阿斯利康(瑞典)有限公司 | 芳基磺酰胺调节剂 |
CA2620333A1 (en) * | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
US20100234349A1 (en) | 2006-09-04 | 2010-09-16 | Olsen Gunnar M | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
DE102008015999B4 (de) | 2008-03-27 | 2011-04-21 | Novar Gmbh | Übertragungsweg - Prüfverfahren für eine Gefahrenmeldeanlage |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
WO2009146030A1 (en) * | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
CN102131791B (zh) | 2008-06-20 | 2014-12-24 | 阿斯利康(瑞典)有限公司 | 二苯并硫杂氮杂*衍生物及其用途 |
AU2009316801C1 (en) | 2008-11-18 | 2015-12-24 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflammatory stimulation |
PT2889033T (pt) | 2008-11-19 | 2018-06-18 | Forum Pharmaceuticals Inc | Tratamento de sintomas negativos da esquizofrenia com (r)-7-cloro-n-(-quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida e sais farmacêuticos resultantes da mesma |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8612002B2 (en) | 2009-12-23 | 2013-12-17 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
US8507516B2 (en) | 2009-10-28 | 2013-08-13 | Bristol-Myers Squibb Company | Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands |
US8278320B2 (en) | 2009-10-28 | 2012-10-02 | Bristol-Myers Squibb Company | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
WO2011137313A1 (en) | 2010-04-30 | 2011-11-03 | Bristol-Myers Squibb Company | Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs |
EP2571874B1 (en) | 2010-05-17 | 2016-03-30 | Forum Pharmaceuticals Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
CN103619405B (zh) | 2011-05-09 | 2015-11-25 | 赛博恩特医疗器械公司 | 用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活 |
GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
ES2694299T3 (es) | 2013-02-07 | 2018-12-19 | Heptares Therapeutics Limited | Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4 |
AU2014282977B2 (en) | 2013-06-21 | 2018-06-14 | Takeda Pharmaceutical Company Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
EP3405255A4 (en) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
US11745039B2 (en) | 2016-07-25 | 2023-09-05 | Tonal Systems, Inc. | Assisted racking of digital resistance |
US10661112B2 (en) | 2016-07-25 | 2020-05-26 | Tonal Systems, Inc. | Digital strength training |
GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
US10617903B2 (en) | 2017-10-02 | 2020-04-14 | Tonal Systems, Inc. | Exercise machine differential |
US10335626B2 (en) | 2017-10-02 | 2019-07-02 | Tonal Systems, Inc. | Exercise machine with pancake motor |
US10589163B2 (en) | 2017-10-02 | 2020-03-17 | Tonal Systems, Inc. | Exercise machine safety enhancements |
US10486015B2 (en) | 2017-10-02 | 2019-11-26 | Tonal Systems, Inc. | Exercise machine enhancements |
US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
IL298193B2 (en) | 2020-05-21 | 2024-01-01 | Feinstein Institutes For Medical Research | Systems and methods for stimulating the vagus nerve |
US11285355B1 (en) | 2020-06-08 | 2022-03-29 | Tonal Systems, Inc. | Exercise machine enhancements |
US11878204B2 (en) | 2021-04-27 | 2024-01-23 | Tonal Systems, Inc. | First repetition detection |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH601304A5 (ja) * | 1974-02-12 | 1978-07-14 | Buskine Sa | |
US4028351A (en) * | 1971-09-07 | 1977-06-07 | Buskine S.A. | Method for the preparation of derivatives of spiro (4,5)-decane and derivatives thus obtained |
GB8808433D0 (en) * | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
GB8816299D0 (en) * | 1988-07-08 | 1988-08-10 | Merck Sharp & Dohme | Therapeutic agents |
US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
IL97726A (en) * | 1990-04-10 | 1994-12-29 | Israel Inst Biolog Res | Pharmaceutical preparations containing compounds with bridged and unbridged heterocyclic groups connected via spiro-atop with oxazoline and thiazoline groups, and sharp compounds |
US5073560A (en) * | 1990-07-20 | 1991-12-17 | Fisons Corporation | Spiro-isoxazolidine derivatives as cholinergic agents |
US5137895A (en) * | 1991-04-29 | 1992-08-11 | A. H. Robins Company, Incorporated | 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols |
-
1995
- 1995-08-22 WO PCT/SE1995/000937 patent/WO1996006098A1/en active IP Right Grant
- 1995-08-22 DK DK95930755T patent/DK0777671T3/da active
- 1995-08-22 DE DE69516524T patent/DE69516524T2/de not_active Expired - Fee Related
- 1995-08-22 UA UA97031329A patent/UA54375C2/uk unknown
- 1995-08-22 HU HU9701965A patent/HUT77352A/hu unknown
- 1995-08-22 EE EE9700039A patent/EE03399B1/xx not_active IP Right Cessation
- 1995-08-22 JP JP50799596A patent/JP3708962B2/ja not_active Expired - Fee Related
- 1995-08-22 CZ CZ1997392A patent/CZ289512B6/cs not_active IP Right Cessation
- 1995-08-22 RU RU97104165A patent/RU2148058C1/ru not_active IP Right Cessation
- 1995-08-22 PT PT95930755T patent/PT777671E/pt unknown
- 1995-08-22 CN CN95195518A patent/CN1056846C/zh not_active Expired - Fee Related
- 1995-08-22 EP EP95930755A patent/EP0777671B1/en not_active Expired - Lifetime
- 1995-08-22 CA CA002196995A patent/CA2196995C/en not_active Expired - Fee Related
- 1995-08-22 KR KR1019970701159A patent/KR100366331B1/ko not_active IP Right Cessation
- 1995-08-22 PL PL95318760A patent/PL183933B1/pl not_active IP Right Cessation
- 1995-08-22 US US08/525,575 patent/US5902814A/en not_active Expired - Fee Related
- 1995-08-22 SK SK216-97A patent/SK282366B6/sk not_active IP Right Cessation
- 1995-08-22 NZ NZ292289A patent/NZ292289A/en not_active IP Right Cessation
- 1995-08-22 BR BR9508751A patent/BR9508751A/pt not_active IP Right Cessation
- 1995-08-22 AT AT95930755T patent/ATE192157T1/de not_active IP Right Cessation
- 1995-08-22 ES ES95930755T patent/ES2145922T3/es not_active Expired - Lifetime
- 1995-08-22 AU AU34018/95A patent/AU690735B2/en not_active Ceased
- 1995-08-22 MX MX9701292A patent/MX9701292A/es unknown
- 1995-08-23 EG EG70395A patent/EG24222A/xx active
- 1995-08-23 IL IL11503995A patent/IL115039A/xx not_active IP Right Cessation
- 1995-08-24 TW TW084108836A patent/TW397837B/zh not_active IP Right Cessation
- 1995-08-24 TR TR95/01053A patent/TR199501053A2/xx unknown
- 1995-11-08 SA SA95160370A patent/SA95160370B1/ar unknown
-
1997
- 1997-02-03 IS IS4424A patent/IS1852B/is unknown
- 1997-02-21 NO NO970800A patent/NO307707B1/no not_active IP Right Cessation
- 1997-02-24 FI FI970762A patent/FI112868B/fi active
-
1998
- 1998-09-26 HK HK98110995A patent/HK1010370A1/xx not_active IP Right Cessation
- 1998-11-09 US US09/188,099 patent/US6051581A/en not_active Expired - Fee Related
-
1999
- 1999-11-08 CN CN99123574A patent/CN1099419C/zh not_active Expired - Fee Related
-
2000
- 2000-04-10 AR ARP000101632A patent/AR031828A2/es unknown
- 2000-07-04 GR GR20000401563T patent/GR3033878T3/el not_active IP Right Cessation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002534525A (ja) * | 1999-01-15 | 2002-10-15 | アストラゼネカ・アクチエボラーグ | 治療において有用なスピロフロピリジンの新規なアラルキルアミン |
JP2001199985A (ja) * | 1999-07-26 | 2001-07-24 | Sumika Fine Chemicals Co Ltd | 高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶 |
JP2006514946A (ja) * | 2002-12-06 | 2006-05-18 | ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート | α7受容体結合コリン作動性アゴニストを用いる炎症の阻害 |
JP2011105745A (ja) * | 2002-12-06 | 2011-06-02 | North Shore-Long Island Jewish Research Inst | α7受容体結合コリン作動性アゴニストを用いる炎症の阻害 |
JP4750421B2 (ja) * | 2002-12-06 | 2011-08-17 | ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト | α7受容体結合コリン作動性アゴニストを用いる炎症の阻害 |
JP2011518831A (ja) * | 2008-04-23 | 2011-06-30 | ブリストル−マイヤーズ スクイブ カンパニー | α−7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン化合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3708962B2 (ja) | 治療に有用なスピロ−アザ二環式化合物 | |
AU784400B2 (en) | New use and novel N-azabicyclo-amide derivatives | |
US6858613B2 (en) | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | |
EP1539764B1 (en) | Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists. | |
AU2005233492B2 (en) | Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-l-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor | |
US5998429A (en) | Azabicyclic esters of carbamic acids useful in therapy | |
AU2003224546B2 (en) | Heterocyclic compounds | |
US6849620B2 (en) | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | |
EP1438308A1 (en) | N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists | |
CA2171579A1 (en) | Piperidine derivatives, process for the preparation thereof and application thereof in therapeutics | |
US20070244097A1 (en) | Nicotinic AcetylcholineReceptor Ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040810 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041110 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050203 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20050203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050726 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050805 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090812 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |